Sequential Use of lndium-111 Labeled Monoclonal Antibodies 96.5 and ZME-018 does not Increase Detection Sensitivity for Metastatic Melanoma
- 1 May 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 14 (5) , 357-366
- https://doi.org/10.1097/00003072-198905000-00011
Abstract
Two indium-111 labeled anti-melanoma murine monoclonal antibodies (MAb), 96.5 and ZME-018, each recognizing separate antigens on melanoma cells, were administered intravenously to 17 patients with melanoma in a sequential fashion to determine whether: 1) additional tumor sites could be imaged with the combination compared to a single MAb; 2) the first MAb influenced the biodistribution and tumor localization of the second; and 3) significant toxicity occurred with the combination. Patients were randomized to receive either 96.5, followed by ZME-018, ZME-018 followed by 96.5, or each MAb followed by itself (controls). Infusions of the second MAb occurred 10 days after the first infusion. Gamma camera images were obtained 72 hours after each antibody infusion. There were 139 known metastatic sites of which 72 lesions were localized by either MAb for an overall sensitivity of 52%. The detection rate was higher when lesions only greater than 1.5 cm were considered. Imaging results were independent of MAb administration sequence. When ZME-018 was given as the first infusion, 53% of known lesions were detected, compared to 34% when ZME-018 was given as a second infusion (p = NS). However, mean sensitivities using 96.5 as the first or second infusion were 48% and 66% respectively (p = NS). There was not a significant number of sites detected by MAb 2 that were missed by MAb 1. Human anti-murine antibody (HAMA) response occurred in seven of eight patients studied; two patients who experienced toxicity had levels of HAMA greater than 2000 ng/ml. We conclude that the use of these two murine anti-melanoma monoclonal antibodies given in sequential fashion did not significantly change the imaging sensitivity from that seen with each individual antibody. Moreover, with the exception of one patient, mean plasma half-life of the MAb did not change significantly, suggesting that overall clearance mechanisms were not saturated by the consecutive doses of monoclonal antibody or significantly altered by the presence of HAMA.Keywords
This publication has 20 references indexed in Scilit:
- Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody: a preliminary report.Radiology, 1985
- Pilot trial of murine monoclonal antibodies in patients with advanced melanoma.Journal of Clinical Oncology, 1985
- Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration.Journal of Clinical Oncology, 1984
- Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon.The Journal of Experimental Medicine, 1984
- Phenotyping of Lesions of Melanocyte Origin With Monoclonal Antibodies to Melanoma-Associated Antigens and to HLA Antigens2JNCI Journal of the National Cancer Institute, 1984
- LEVEL OF A MEMBRANE-BOUND HIGH-MOLECULAR-WEIGHT MELANOMA-ASSOCIATED ANTIGEN AND A CYTOPLASMIC MELANOMA-ASSOCIATED ANTIGEN IN SURGICALLY REMOVED TISSUES AND IN SERA FROM PATIENTS WITH MELANOMA1984
- Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.The Journal of Immunology, 1981
- Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.Proceedings of the National Academy of Sciences, 1981
- Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.Proceedings of the National Academy of Sciences, 1979
- Covalent attachment of chelating groups to macromoleculesBiochemical and Biophysical Research Communications, 1977